Cargando…

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

PURPOSE: Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration in patients with metastatic breast cancer (MBC) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Chengcheng, Xie, Yizhao, Zhao, Yannan, Li, Yi, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Hu, Xichun, Wang, Biyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793024/ https://www.ncbi.nlm.nih.gov/pubmed/36582188 http://dx.doi.org/10.1177/20420986221146411

Ejemplares similares

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2019)

Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
por: Chun, Jung Won, et al.
Publicado: (2021)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
por: Wang, Biyun, et al.
Publicado: (2022)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
por: Jung, Kwangrok, et al.
Publicado: (2022)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
por: Domadia, Kshitij, et al.
Publicado: (2021)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
por: Xu, Ruihua, et al.
Publicado: (2017)

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study
por: Chang, Chen, et al.
Publicado: (2022)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
por: Prejac, Juraj, et al.
Publicado: (2022)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience
por: Lo Re, Giovanni, et al.
Publicado: (2015)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vu11i09ca89flf7ennqm6jj2ms